Ursapharm Arzneimittel

What Ursapharm Arzneimittel does

Ursapharm Arzneimittel GmbH is a privately held, Germany-headquartered pharmaceutical manufacturer founded in 1974 in Saarbrücken, with a workforce of more than 950 employees. The company develops, produces, and markets prescription pharmaceuticals, medical devices, and food supplements, with a clear specialization in ophthalmology (dry eye and ocular surface disease), supported by adjacent lines in nasal health, eyelid hygiene, ocular nutrition, venous health, and general practice.

The company's technical core consists of two proprietary delivery platforms developed in-house: the COMOD® system (introduced 1993), a preservative-free multi-dose container that enables long-term sterile storage of liquid dosage forms without preservatives, and the 3K® pump (introduced 1997), a non-airless system used in nasal applications. These platforms underpin the flagship HYLO® family of hyaluronic-acid-based eye drops (HYLO COMOD®, HYLO GEL®, HYLO CARE®, HYLO PARIN®, HYLO FRESH®, HYLO DUAL®, HYLO DUAL INTENSE®, HYLO NIGHT®) plus the water-free EvoTears® formulation using perfluorohexyloctane for lipid phase disorders. Manufacturing is performed in clean-room facilities at the Saarbrücken headquarters, covering sterile liquids, semi-solids, and solid dosage forms, with a separate contract manufacturing (Lohnfertigung) offering.

Revenue is generated through the sale of branded prescription and OTC products distributed exclusively through pharmacies, both in Germany and across 16 export markets in Europe and India; HYLO GEL® additionally benefits from statutory health insurance reimbursement following a G-BA confirmation of unique efficacy. Customers are individual patients and the prescribing/recommending network of physicians and pharmacists rather than enterprise accounts.

Name

Ursapharm Arzneimittel

Legal name

URSAPHARM Arzneimittel GmbH

Website

https://ursapharm.de

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ursapharm Arzneimittel GmbH is a privately held German pharmaceutical manufacturer specializing in ophthalmology, especially dry eye treatments, using its proprietary COMOD® preservative-free delivery platform across the HYLO® family and EvoTears®, distributed through pharmacies in 16 countries.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Ophthalmic Goods (3851), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmic & Otic Generics (HLAIABAF)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Topical & Dermatology Generics (HLAIABAE), Professional Skincare & Facial Treatments (CRABALAF)

Keywords

• Ophthalmic pharmaceuticals
• Dry eye treatments
• Preservative-free formulations
• Nasal care products
• Generic medicines

Headquarters

HQ city

Saarbrücken

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: URSAPHARM generates revenue through the sale of prescription and OTC pharmaceutical products including eye care medications (HYLO® family), general practice medicines (Bromelain-POS®, Zinkorotat-POS®, Veno SL® 300, BilanCyn®), and medical devices. Products are sold through pharmacy distribution channels with pricing at point of sale.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

URSAPHARM Arzneimittel GmbH develops, manufactures and distributes pharmaceutical products and medical devices, with its core focus on ophthalmology and the HYLO® family of preservative-free hyaluronic acid eye drops and EvoTears® lipid replacement therapy for dry eye syndrome. The portfolio also extends to general practice medicines (Bromelain-POS®, Zinkorotat-POS®, Veno SL® 300, BilanCyn®), nasal health products (hysan®), eyelid hygiene products (POSIFORLID®), food supplements (Retaron® Makula Omega 3, aronia+) and facial skin care (skjur®), all produced at clean-room facilities in Saarbrücken, Germany using proprietary COMOD® and 3K® delivery systems.

Product overview

URSAPHARM Arzneimittel GmbH is one of the world's leading manufacturers in ophthalmology, producing pharmaceuticals, medical devices, and food supplements. The company's core product portfolio centers on the HYLO® family of eye drops (including HYLO COMOD®, HYLO GEL®, HYLO DUAL®, HYLO DUAL INTENSE®, HYLO CARE®, HYLO FRESH®, HYLO PARIN®, HYLO NIGHT®, and EvoTears®) for various dry eye conditions, using proprietary COMOD® and 3K® delivery systems. Additional products include POSIFORLID® for eyelid hygiene, hysan® for nasal health, Retaron® Makula Omega 3 for ocular vitamins, Bromelain-POS® for general practice, Zinkorotat-POS® for zinc supplementation, Veno SL® 300 for venous health, BilanCyn® Verdauungskapseln for digestion, and aronia+ food supplements. The company also offers contract manufacturing services (Lohnfertigung) and skin care products under the skjur® brand.

Differentiator

Problem solved

Functional benefit

Brands

• HYLO: Product range providing eye moisturisation, wetting and care with a system for all severities and types of dry eye, including HYLO COMOD, HYLO GEL, HYLO DUAL, HYLO FRESH, HYLO CARE, HYLO PARIN, HYLO NIGHT, HYLO DUAL INTENSE, and EvoTears products.
• POSIFORLID
• hysan
• aronia+
• Bromelain-POS
• EvoTears
• Veno SL 300
• Zinkorotat-POS
• Retaron Makula Omega 3
• BilanCyn Verdauungskapseln
• skjur

Products and services

• HYLO COMOD® Classic preservative-free and phosphate-free eye drops containing 0.1% sodium hyaluronate delivered via the COMOD® system, providing long-lasting lubrication of dry eyes.
• HYLO GEL® High-viscosity, preservative-free, phosphate-free eye drops with 0.2% sodium hyaluronate delivering intensive, long-lasting lubrication for severe chronic dry eyes without impairing vision.
• HYLO DUAL® Preservative-free eye drops combining ectoine and 0.05% sodium hyaluronate for dual-action lubrication and stabilization of the tear film's lipid layer, relieving inflammation and allergy symptoms.
• HYLO DUAL INTENSE® Intensive-treatment preservative-free eye drops with 0.2% hyaluronic acid and 2% ectoine for moderate to severe chronic dry eye with inflammatory symptoms.
• HYLO CARE® Preservative-free eye drops with dexpanthenol and 0.1% sodium hyaluronate providing intensive therapeutic care, restoring the cornea's natural protective barrier and supporting wound healing.
• HYLO FRESH® Preservative-free eye drops with Euphrasia and 0.03% sodium hyaluronate that refresh and relieve tired, stressed eyes caused by environmental factors.
• HYLO PARIN® Preservative-free eye drops with heparin and 0.1% sodium hyaluronate for enhanced lubrication and regeneration of irritated cornea and conjunctiva.
• HYLO NIGHT® Preservative-free eye ointment with vitamin A for night-time lubrication, protecting the eye surface during sleep and relieving burning, dry or tired eyes.
• EvoTears® Water-free eye drops with perfluorohexyloctane for lipid replacement therapy, providing protection against tear evaporation for dry eyes caused by lipid phase disorder.
• POSIFORLID® Lid hygiene line including wipes and eye spray for the daily cleaning and care of eyelids, targeting eyelid inflammation (blepharitis).
• hysan® Nasal Health range Nasal health products for nasal care, moisturization and hygiene, delivered through the COMOD®/3K® non-airless container system.
• Retaron® Makula Omega 3 Food supplement with zinc and DHA from concentrated fish oil, with aronia berry extract, lutein, zeaxanthin, selenium and vitamins C and E to help maintain normal vision.
• Bromelain-POS® Plant-based product containing pineapple enzyme bromelain for acute swelling from strains, sprains or bruising, accelerating healing and reducing pain.
• Zinkorotat-POS® Zinc supplement (zinc orotate) with high bioavailability in a stomach-friendly formula supporting immune function and wound healing for zinc deficiency.
• Veno SL® 300 Capsules containing troxerutin for the treatment of spider veins and heavy legs, preventing fluid accumulation in tissue and improving circulation.
• BilanCyn® Verdauungskapseln Artichoke-based digestive capsules for symptomatic relief of digestive disorders with bloating or flatulence; lactose-free and vegan.
• aronia+ food supplements (incl. aronia+ PRO IMMUN) Aronia-berry-based food supplement line including aronia+ PRO IMMUN direct granules with zinc and selenium for immune system support.
• skjur® Facial Care Facial care product line formulated for sensitive skin.

Quantifiable outcome

• 60% of dry eye cases are caused by lipid phase disorders treatable with EvoTears®
• +4 more outcomes

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Abdi İbrahim İlaç Sanayi ve Ticaret A.Ş.minorStrategic or Co-development Partner · 1 February 2025Turkey-based Abdi İbrahim partnered with Japan-based Rohto Pharmaceutical to launch TearShield-based eye care products in Turkey. This is mentioned in the context of market trends in the global dry eye products market, showing competitive activity in the ophthalmology sector.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Rohto Pharmaceutical: Rohto is a Japanese OTC eye care leader with global ambitions in lipid-based and dry eye therapies (e.g., TearShield mentioned in market context). It competes with Ursapharm's EvoTears lipid replacement franchise in Asia and is increasingly visible in Europe.
• Santen Pharmaceutical: Santen is a Japan-based global specialty ophthalmology company with a strong dry eye and ocular surface portfolio (e.g., Ikervis, Cationorm) and European commercial presence. It is a direct peer in preservative-free dry eye therapies and ophthalmic medical devices.
• OmniVision Pharma: OmniVision is a Germany-based specialist in ophthalmology pharmaceuticals distributed through pharmacy channels, with direct overlap to Ursapharm's portfolio on dry eye and ocular surface products in the German market.
• Alcon: Alcon is the world-leading eye care company with deep dry eye (Systane), surgical, and vision care franchises. It overlaps with Ursapharm across preservative-free artificial tears and OTC eye care sold through pharmacies globally.
• Bausch + Lomb (Bausch Health): Bausch + Lomb is a global ophthalmology powerhouse with a broad dry eye and ocular surface portfolio (e.g., Soothe, Artelac, Blink), directly competing with Ursapharm's HYLO family in OTC dry eye treatments across the same pharmacy distribution channel.
• Théa Pharma: Théa is a France-based independent ophthalmology company with a broad dry eye and ocular surface portfolio (Thealoz, Hyabak) using similar preservative-free multi-dose technology. It is one of Ursapharm's most direct European competitors in preservative-free hyaluronic acid dry eye drops.

Emerging players

• Nicox: Nicox is a France-based ophthalmology company developing and commercializing novel therapeutics for ocular surface and glaucoma, including Vyzulta partnerships. It represents a smaller, R&D-driven European ophthalmic peer alongside Ursapharm.

Broad incumbents

• Johnson & Johnson Vision: Johnson & Johnson Vision operates across contact lenses, surgical ophthalmology, and ocular surface (e.g., Blink tears). Its scale and brand presence in eye care make it a strategic benchmark for Ursapharm in dry eye and contact-lens-adjacent drops.
• AbbVie (Allergan Aesthetics / Eye Care): AbbVie inherited Allergan's ophthalmology franchise (Restasis, Refresh) and competes broadly in dry eye pharmaceuticals and ocular surface disease. It is a deep-pocketed incumbent shaping prescriber preferences Ursapharm must compete against.
• Novartis (Ophthalmology / Sandoz): Novartis has historically led global ophthalmology pharmaceuticals and continues through Sandoz generics. Its broader portfolio and deep R&D set the innovation and pricing benchmark Ursapharm's generic-adjacent ophthalmic products must compete against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ursapharm Arzneimittel